Oxford Ovarian Cancer Predict Chemotherapy Response 01 (OXO-PCR-01)
The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy|
- Correlation between βIII tubulin expression and Mitotic Index (MI) following single agent paclitaxel treatment [ Time Frame: Before and 24-hours after paclitaxel treatment ] [ Designated as safety issue: No ]Correlation between βIII tubulin expression and Mitotic Index (MI) before and after single agent paclitaxel treatment to determine whether overexpression of βIII tubulin is associated with Paclitaxel resistance
- Correlation between mitotic index and the magnitude of CA125 response [ Time Frame: three weeks after paclitaxel treatment ] [ Designated as safety issue: No ]Correlation between mitotic index and the magnitude of CA125 response will be analysed to investigate whether post-paclitaxel mitotic index is a determinant of clinical response in ovarian cancer
Biospecimen Retention: Samples With DNA
Ovarian cancer biopsy tissue samples Eyebrow hair follicles Blood samples Surgical tissue samples
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
While paclitaxel is very effective in killing cancer cells in a proportion of patients, some patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated with unpleasant side effects. We are doing this study to try and understand what is happening in cancer cells in different individuals after paclitaxel treatment that make them respond differently to the same treatment. We hope that this study will enable us to develop a method to identify women who are suitable for this form of treatment. We also want to understand why some cancer cells don't get killed with paclitaxel. This information will help us to select treatment to suit an individual patient, and thus improve the outcome of treatment and avoid giving treatment that will not benefit the patient.
|Contact: Ahmed A Ahmedfirstname.lastname@example.org|
|Oxford, United Kingdom|
|Principal Investigator: Ahmed A Ahmed|